Allergy to short-acting β2-agonists in a COPD patient: Is an immunological mechanism involved?

Short-acting 2-agonists (SABA) are used in asthma and chronic obstructive pulmonary disease (COPD) treatment because of their capacity to relax smooth muscle, their rapid symptoms relief and their acceptable safety profile. Salbutamol and terbutaline are the most frequently used SABA. Although SABA present an acceptable safety profile as above-mentioned, several adverse effects have been described, most of them related to their effect over 2-adrenoceptor (especially tremor, palpitation and elevated heart rate). In addition to these side effects, some allergic reactions (including an anaphylactic reaction and occupational asthma in workers) and paradoxical bronchoconstriction have also been described after SABA treatment. Paradoxical bronchoconstriction is characterised by the presence of respiratory symptoms (bronchospasm, wheezing, coughing or dyspnoea) and sometimes a fall in forced expiratory volume in 1 s (FEV1) measured by spirometry, immediately after the administration of a bronchodilator drug. These episodes have been related with different immunological and non-immunological mechanisms; unfortunately, the underlying mechanism has not been described, even though in vitro and in vivo analyses have been carried out. We report the case of a 60-year-old man diagnosed with COPD who suffered a near--fatal respiratory exacerbation during the month of May. He was sent to our out-patient clinic to study the possible implication of pollen allergy. At the time of his visit in June, he was asymptomatic and treated with salmeterol/fluticasone. First of all, skin prick tests (SPTs) for the most common aeroallergens eliciting respiratory symptoms in our country were performed, obtaining positive results for Olea europea pollen. Spirometry and measurement of the improvement of lung function after inhalation of SABA were also performed, obtaining normal values and negative bronchodilator test. The patient was re-evaluated one year later and spirometry with bronchodilator test was performed. Less than 5 min after the administration of 200 g of inhaled salbutamol, the patient experienced generalised itching and erythema, chest tightness with audible wheezes and a 46% fall in FEV1 (from 2.45 to 1.52 l). An inhalation of salmeterol/fluticasone, dexchlorpheniramine 5 mg and methylprednisolone 60 mg intravenous were administered, obtaining partial improvement in 15 min and total recovery in about 2 h. Re-interrogated, the patient referred that similar symptoms had previously appeared after salbutamol inhalation in the last six months. Because of the necessity of the use of SABA in this patient, as treatment for COPD acute exacerbations, an allergic study was performed. One month after the reaction the patient underwent an allergy workup at our allergy department. SPT with salbutamol (0.5 mg/ml, as previously described), terbutaline (0.3 mg/ml) and latex, and intradermal skin test with terbutaline (0.03 and 0.003 mg/ml) were performed, obtaining negative results for all of them. All drugs were tested in three healthy control subjects, obtaining negative results. As the patient presented symptoms suggesting an anaphylactic reaction on several occasions, a challenge with inhaled salbutamol was not performed. Challenge with other SABA (terbutaline) was regarded as an alternative for treatment. The patient signed an informed consent statement for drug challenge. Inhaled placebo and terbutaline with spirometric control (before, 5, 30 and 60 min after inhalation) were administered. First of all, placebo inhalation was administered, the patient was observed for 1 h having no symptoms and spirometric control was also performed showing no changes. Then, one terbutaline 500 g inhalation was administered. Five minutes after the inhalation the patient felt out of breath, and presented cough and audible wheezes. Spirometric control showed a 35% fall in FEV1. Intravenous methylprednisolone (60 mg) was administered obtaining a total recovery, including spirometric values, in about 1 h. Terbutaline challenge was considered positive. After two reactions to SABA, no other SABA were tested. Inhalation challenges with longacting 2 agonists (LABA) salmeterol and formoterol were performed as previously described, and both of them were well tolerated. Trying to elucidate the immunological mechanism underlying these reactions, a basophile activation test (BAT) with both implicated SABA was carried out. BAT (Basotest, ORPEGEN Pharma, Heidelberg, Germany) was performed using whole blood obtained from the patient and a control, as previously described. Drug concentrations were 0.8, 4, and 20 g/ml for salbutamol and terbutaline. No basophile activation was observed for both SABA at any concentration (Fig. 1). In 2007, Bonniaud et al. described the case of a patient who suffered a paradoxical bronchoconstriction in which